New Weight-Loss drug candidate enters early human testing
NCT ID NCT07170319
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study is testing a new drug called IBI3032 in 79 adults who are overweight or have obesity. The main goal is to check if the drug is safe and how the body processes it over a 4-week treatment period. Participants receive either the drug or a placebo, and researchers monitor side effects and drug levels in the blood. This is a first step to see if IBI3032 might help control weight, but it is not yet proven as a treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
79 people
The number who actually took part.
- Started
-
Sep 2025
- Expected to finish
-
Mar 2026
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 65 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Healthy male or females, as determined by medical history * Have safety laboratory results within normal reference ranges Exclusion Criteria: * Have known allergies toIBI3032, glucagon-like peptide-1 (GLP-1) analogs, related compounds * Abnormal electrocardiogram (ECG) at screening * Significant history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological or neurological disorders.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Overweight or obesity are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Frist Affiliated Hospital of Anhui Medical University
Hefei, Anhui, 230000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an experimental injection help people with obesity shed pounds?
- A cup of beans a day: could it calm inflammation and boost insulin response?
- Can a new pill help fight obesity? a trial puts HRS-7535 to the test
- Could shedding pounds be the key to silencing chronic back pain?
- Could a new injection help tackle obesity? a safety trial begins
- Can a new injection help tackle obesity and diabetes? a safety trial begins